 |
|
Delivering What's Next
2003 was a year of unprecedented accomplishment for
Boston Scientific. We made significant strides throughout the company.
We experienced solid growth across the organization and became the
leader in the international drug-eluting stent market. Most significantly,
we recently received approval from the U.S. Food and Drug Administration
to market our TAXUS™ Express2™ paclitaxel-eluting coronary
stent system in the United States, positioning us for worldwide
leadership in the treatment of coronary artery disease.
|
|
| Product testing is an important part
of Boston Scientific’s quality program. Pictured above is advanced
equipment used to measure the strength of our product components. |
|
 |
|
